Related Experiment Videos

Association of angiotensin I-converting enzyme gene insertion/deletion polymorphism with rheumatic heart disease in

Usha Gupta1, Avshesh Mishra, Saurabh S Rathore

  • 1Department of Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow, 226014, India.

Insights

The angiotensin I-converting enzyme (ACE) ID and DD genotypes are linked to a higher risk of rheumatic heart disease (RHD), especially combined valve lesions. This suggests ACE gene polymorphism plays a role in RHD development.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Rheumatic Heart Disease Pathogenesis

Background:

  • Rheumatic heart disease (RHD) is a severe sequela of rheumatic fever.
  • The angiotensin I-converting enzyme (ACE) is implicated in valvular fibrosis and calcification in RHD pathogenesis.

Purpose of the Study:

  • To investigate the association between ACE I/D polymorphism and RHD in the Indian population.
  • To evaluate the role of ACE I/D genotypes in the pathogenesis of RHD, including specific valve lesions.

Main Methods:

  • A case-control study involving 300 RHD patients and 200 controls.
  • ACE I/D polymorphism identified using polymerase chain reaction.
  • Meta-analysis of the current study and three published studies (636 RHD cases, 533 controls).

Main Results:

  • Significant differences in ACE ID and DD genotype distributions were observed between RHD cases and controls (ORs 1.62-2.08).
  • ACE ID and DD genotypes were significantly associated with combined valve lesions (CVL) in RHD patients (FDR Pcorr < 0.014).
  • Meta-analysis indicated an association between the ACE D allele and RHD risk (OR 1.22).

Conclusions:

  • ACE ID and DD genotypes are associated with an increased risk of RHD.
  • The ACE I/D gene polymorphism appears to play a significant role in the pathogenesis of RHD, particularly in cases with combined valve lesions.

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...